In the RE-DUAL PCI trial, 2725 patients with AF who had undergone PCI were randomized to a dual therapy regimen of dabigatran 110 mg or 150 mg plus P2Y12 inhibitor or triple therapy with VKA plus DAPT [21]. This evidence concerns the gene P2RY12 and atrial fibrillation.